[
  {
    "ts": null,
    "headline": "Biogen Highlights the Potential of Felzartamab for a Range of Immune-Mediated Diseases including Three Phase 3 Programs in Rare KidneyDiseases",
    "summary": "Cambridge - Biogen Inc. will host a virtual investor seminar today at 10:00 a.m. ET focused on the potential of the investigational drug felzartamab in rare kidney diseases and the potential to...",
    "url": "https://finnhub.io/api/news?id=9bd46aa422c7c828c4d302b074c969b75a1737fa5db68a84075402511b587eae",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749724079,
      "headline": "Biogen Highlights the Potential of Felzartamab for a Range of Immune-Mediated Diseases including Three Phase 3 Programs in Rare KidneyDiseases",
      "id": 135212829,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "Cambridge - Biogen Inc. will host a virtual investor seminar today at 10:00 a.m. ET focused on the potential of the investigational drug felzartamab in rare kidney diseases and the potential to...",
      "url": "https://finnhub.io/api/news?id=9bd46aa422c7c828c4d302b074c969b75a1737fa5db68a84075402511b587eae"
    }
  },
  {
    "ts": null,
    "headline": "Biogen: positive Phase 3 data in lupus",
    "summary": "Biogen and UCB have announced additional detailed results from the Phase 3 PHOENYCS GO study evaluating their investigational drug dapirolizumab pegol at the annual meeting of the European League...",
    "url": "https://finnhub.io/api/news?id=25c6750499650517d00436206548002809363ab890d43691826e63252333bacd",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749717567,
      "headline": "Biogen: positive Phase 3 data in lupus",
      "id": 135211705,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "Biogen and UCB have announced additional detailed results from the Phase 3 PHOENYCS GO study evaluating their investigational drug dapirolizumab pegol at the annual meeting of the European League...",
      "url": "https://finnhub.io/api/news?id=25c6750499650517d00436206548002809363ab890d43691826e63252333bacd"
    }
  },
  {
    "ts": null,
    "headline": "Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity",
    "summary": "Dapirolizumab pegol (DZP) showed efficacy across multiple clinical endpoints in the PHOENYCS GO study, including fatigue and measures of disease activityDZP showed consistent improvements in fatigue, a common and debilitating symptom of systemic lupus erythematosus (SLE)At Week 48, more individuals receiving DZP experienced no or low disease activity compared to standard of care with differences observed as early as Week 12 BRUSSELS and CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- UCB (Eu",
    "url": "https://finnhub.io/api/news?id=9369c1f4fb2438e1d3737be6c3b1285a7933c98b4105b7f7e79d39c7d1c7d489",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749704400,
      "headline": "Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity",
      "id": 135205990,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Dapirolizumab pegol (DZP) showed efficacy across multiple clinical endpoints in the PHOENYCS GO study, including fatigue and measures of disease activityDZP showed consistent improvements in fatigue, a common and debilitating symptom of systemic lupus erythematosus (SLE)At Week 48, more individuals receiving DZP experienced no or low disease activity compared to standard of care with differences observed as early as Week 12 BRUSSELS and CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- UCB (Eu",
      "url": "https://finnhub.io/api/news?id=9369c1f4fb2438e1d3737be6c3b1285a7933c98b4105b7f7e79d39c7d1c7d489"
    }
  }
]